PUBLIC STRATEGIES WASHINGTON, INC.

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $30,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Medicare/Medicaid

Issues related to the coverage of obesity therapeutics

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem